The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V

AIDS

Volumn 24, Issue 5, 2010, Pages 779-781

  Knops, Elena ^a   Kemper, Ina ^a   Schülter, Eugen ^a   Pfister, Herbert ^a   Kaiser, Rolf ^a   Verheyen, Jens ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; GAG PROTEIN; INDINAVIR; ISOLEUCINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VALINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PYRIMIDINONES; SEQUENCE ANALYSIS, DNA;

EID: 77949356168     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328336784d     Document Type: Article

References (10)

1. Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 2009; 200:698-709.
2. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
3. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009; 5:e1000345.
4. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. Gag determinants of fitness and drug susceptibility in protease inhibitor resistant HIV-1. J Virol 2009; 83:9094-9101.
5. Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 2006; 11:879-887.
6. Verheyen J, Knops E, Kupfer B, Hamouda O, Somogyi S, Schuldenzucker U, et al. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients. J Infect 2009; 58:61-67.
7. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223.
8. Van Marck H, Dierynck I, Kraus G, Hallenberger S, Pattery T, Muyldermans G, et al. The impact of individual HIV-1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence. J Virol 2009; 83:9512-9520.
9. Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamo-nica P, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir mono-therapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.
10. van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2007; 195:399-409.